Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Lyon 1 EPHE

Home page

Rare thoracic tumors

Rare tumors in humans, a challenge for research

Rare cancers are defined by an incidence of less than 3/100 000 people per year. The scarcity of animal models or of ex vivo cellular systems and the limited number of cases are detrimental for to the study of these tumors. Through its clinical implementation, our team relies on its scientific and medical expertise to develop translational research as well as new ex vivo study tools. 

RETRO_EN

Our work aims to understand the cellular and molecular mechanisms involved in the development of:

  • Bronchioloalveolar carcinoma or predominantly lepidic mixed adenocarcinoma is characterized by a peculiar epidemiology and its analogies with JSRV-induced lung cancers in small ruminants. Comparative studies in humans and animals allows us to decipher deregulation associated with lepidic lesions.
  • Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease affecting mainly women and considered as a low grade metastatic neoplasm. The disease is characterized by infiltration into the lung and lymphatic vessels of smooth muscle-like cells. S We are working on the deregulation of signaling pathways and the potential of anti-tumor drugs.
  • Thymomas are rare malignant tumors of variable evolution and prognosis associating tumor epithelial cells and resident lymphocytes. Their aggressiveness is related to the frequency of tumor recurrence after surgery. We develop ex vivo study models derived from patient' tissues to study deregulation of pathways controlling cell proliferation.

Financial suppport from LYric